Next 10 |
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Turning Point Therapeutics press release ( NASDAQ: TPTX ): Q2 GAAP EPS of -$2.48 misses by $0.78 . Revenue of $0.12M (-97.7% Y/Y) misses by $2.15M . For further details see: Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M ...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administ...
Update 11:20am: Adds German filing from late Thursday. Bristol Myers Squibb ( NYSE: BMY ) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics ( NASDAQ:...
Bristol Myers Squibb ( NYSE: BMY ) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics ( NASDAQ: TPTX ), according to a Dealreporter item. The ac...
The Health Care sector of the S&P 500 was in the red this month, with the Health Care Select Sector SPDR ETF ( XLV ) finishing 3% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics...
The eleven sectors of the S&P 500 were 16.4% lower for Q2 2022, with SPDR S&P 500 Trust ETF closed more than 16% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics ( TPTX ) +179.1...
NEW YORK, NY / ACCESSWIRE / June 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Steel Connect, Inc. (NASDAQ:STCN)'s ...
Bristol-Myers hits new highs, partly due to investors piling into drug stocks with the economy facing a potential recession. The biopharma faces the loss of exclusivity, or LOE, on its largest drug Revlimid while launching new drugs with the potential to replace the lost revenues of t...
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that consider...
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...